<DOC>
	<DOCNO>NCT02560649</DOCNO>
	<brief_summary>The aim current study investigate whether HBsAg clearance rate improve apply RGT ( ( Response-Guided Therapy ) strategy HBeAg positive CHB ( chronic hepatitis B ) patient treat nucleoside analogue ( NUC ) achieve HBVDNA &lt; 1000copies/ml，and HBsAg &lt; 5000IU/ml ; &amp; HBeAg &lt; 100PEIU/ml ( or470s/co ) , combine PEG-IFN a-2a 24 week .</brief_summary>
	<brief_title>An Exploratory Study RGT Strategy Optimal NUC-experienced Patients</brief_title>
	<detailed_description>The current study prospective , randomize , open , multi-center investigation . The aim current study investigate whether HBsAg clearance rate improve apply RGT strategy HBeAg positive CHB patient treat NUC achieve HBVDNA &lt; 1000copies/ml，and HBsAg &lt; 5000IU/ml ; &amp; HBeAg &lt; 100PEIU/ml ( or470s/co ) , combine PEG-IFN a-2a 24 week . Then subject divide three group accord qHBsAg level week 24 ( RGT ) . For subject qHBsAg &lt; 200IU/ml week 24 , define Group A ; subject Group A continue treat NUC combine PEG-IFN a-2a 180μg another 24 week ( total 48 week ) . If qHBsAg week 24 achieve minor 200IU/ml , subject randomize 2 group : Group B : subject continue treat NUC combine PEG-IFN a-2a 180μg another 24 week ( total 48 week ) ; Group C : subject treat NUC 48 week .</detailed_description>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . Male female patient age ≥18 ≤65 year ; 2 . There evidence HBsAg HBeAg positive 6 month HBsAb HBeAb negative treat nucleoside analogue ( NUC ) ( except telbivudine ) ; 3 . Treated NUC ( except telbivudine ) 24 week achieve HBV DNA &lt; 1000copies/ml HBsAg &lt; 5000IU/ml； &amp; HBeAg &lt; 100PEIU/ml ( 470s/co ) ; 4 . Without contraindication Peginterferon alfa2a therapy detailed label ; 5 . Without coinfection hepatitis C , hepatitis D HIV ; 6 . Women without ongoing pregnancy breast feed willing take effective contraceptive measure treatment 7 . Agree participate study sign patient inform consent form . Exclusion criteria 1 . Coinfection active hepatitis A , hepatitis C , hepatitis D and/or human immunodeficiency virus ( HIV ) 2 . AFP ( alpha fetoprotein ) &gt; 50ng/ml and/or evidence hepatocellular carcinoma 3 . Evidence decompensated liver disease ( ChildPugh score &gt; 5 ) . ChildPugh &gt; 5 mean , one follow 6 condition meet , patient exclude : Serum albumin &lt; 35 g/L Prothrombin time prolonged≥ 4 second PTA ( prothrombin activity ) &lt; 60 % Serum bilirubin &gt; 34 µmol/L History encephalopathy Ascites 4 . History evidence medical condition associate chronic liver disease viral hepatitis ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease , alcoholic liver disease , toxin exposure , thalassemia ) 5 . Pregnant breastfeed Women 6 . ANC ( absolute neutrophil count ) &lt; 1.5x 10^9/L PLT ( platelet count ) &lt; 90x 10^9/L 7 . Consuming alcohol excess 20g/day woman 30g/day men within 6 month prior enrollment 8 . History severe psychiatric disease , especially depression . Severe psychiatric disease define major depression psychosis treat antidepressant medication major tranquilizer therapeutic dos respectively time prior 3 month history follow : suicidal attempt hospitalization psychiatric disease , period disability due psychiatric disease 9 . History immunologically mediate disease , ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , rheumatoid arthritis etc . ) 10 . History esophageal varix bleed evidence esophageal varix bleed symptom consistent decompensated liver disease 11 . History chronic pulmonary disease associate functional limitation 12 . History severe cardiac disease ( e.g. , NYHA Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) 13 . Hemodialysis patient patient renal insufficiency 14 . History severe seizure disorder current anticonvulsant use 15 . Major organ transplantation evidence severe illness , malignancy , condition , would make patient , opinion investigator , unsuitable study 16 . History thyroid disease poorly control prescribed medication 17 . Evidence severe retinopathy clinically relevant ophthalmologic disorder 18 . History severe disease evidence severe disease illness condition investigator believe patient suitable join study 19 . Immunomodulatory treatment ( include interferon ) LDT ( telbivudine ) within 1 year prior first dose treatment 20 . Patients include another trial give investigational drug within 12 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>